Publications by authors named "J von Tresckow"
Article Synopsis
- The study explores a new treatment approach for chronic lymphocytic leukemia (CLL) combining bendamustine debulking followed by ofatumumab and ibrutinib, targeting patients with higher tumor loads.
- Out of 65 analyzed patients, 92% showed a response to the treatment, with 14% achieving minimal residual disease negativity, indicating a significant reduction of cancer cells.
- The treatment was generally well-tolerated with common side effects being manageable, and the ongoing maintenance aims to improve outcomes, although ibrutinib remains effective as a standalone therapy in non-trial settings.
In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three phase III trials of the German CLL Study Group (GCLLSG) (CLL8, CLL10, CLL11) including a total of 2159 patients receiving first line (immuno)-chemotherapy (FCR, FC, CLB, CLB-R, CLB-Ob) were analyzed.
View Article and Find Full Text PDFBackground: Chronic lymphocytic leukemia (CLL) mainly affects older persons and is the commonest form of leukemia, with an incidence of 6 cases per 100 000 per- sons per year. In Germany, approximately 1000 men and 850 women die of CLL each year.
Methods: This review is based on pertinent publications retrieved by a selective literature search in PubMed and on the authors' scientific and clinical experience.